With the clinic in sight, Greg Verdine’s startup bags $178M for new class of targeted therapies

ARCH Venture Partners is buying into Greg Verdine’s vision for a world where no targets are off-limits — with the goal of finally pushing the first drug into the clinic.

The size of the Series D financing — $178 million — matches the grand ambitions FogPharma has sketched out with its Helicon compounds, a new class of polypeptide drugs it says combines the cell-penetrating capacity of small molecules with the target-engaging tenacity of biologics.

The biotech is hoping to file an IND for FOG-001, a TCF-blocking β-catenin inhibitor, by mid-2023, a few months behind a Q4 2022 projection that Verdine offered up at the time of Fog’s $107 million Series C in spring 2021. It’s also lining up a slate of programs hitting cancer targets that have been out of reach by other approaches: TEAD, NRAS, Pan-KRAS, ERG and Cyclin E1.

Verdine, a chemist at Harvard and serial entrepreneur, launched FogPharma in 2016 with the idea for a “brace” that would lock polypeptide structures in place so that they can better penetrate cells, home in on specific targets and stay in the body for longer.

Rick Klausner

In conjunction with the round, he’s also recruited Rick Klausner — the former National Cancer Institute chief of Juno, Lyell and now Altos Labs fame — to the board of directors.

These Helicon polypeptides, Verdine said, “represent the future of precision medicine.”

The round featured two other new investors, Milky Way Investments and Fidelity Management & Research Company, as well as a group of existing investors. Other backers include VenBio Partners, Deerfield Management, GV, Cormorant Asset Management, funds and accounts advised by T. Rowe Price Associates, Invus, Farallon Capital Management, HBM Healthcare Investments, Casdin Capital, and PagsGroup.

small molecules
biologics
biotech
healthcare